Spectrum Pharma (SPPI) fails to win FDA panel backing
- Wall St. set to rise ahead of Trump inauguration
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Herbalife (HLF) Says SEC Requested Documents on Anti-Corruption Compliance in China; Reviewed with DoJ
- Investment Focus: History suggests Trump month will be stocks down, dollar up
- General Electric (GE) Reports In-Line Q4 EPS
News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.
Spectrum Pharma (NASDAQ: SPPI) fails to win FDA panel backing
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Bristol-Myers Squibb (BMY) volatility low into saying it won’t seek accelerated approval for lung cancer combination treatment
- Herbalife (NYSE: HLF) volatility low into disclosed that the SEC has requested documents and other information
- Stocks with Implied Volatility Movement
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!